Article

CDK9 pharmacological inhibition with PRT2527 has antitumor activity in marginal zone lymphoma models and can improve the effects of BTK, PI3K, and BCL2 inhibitors

2026-02-11

Abstract excerpt

Cyclin-dependent kinase 9 (CDK9) drives transcriptional elongation and supports the expression of short-lived oncogenic and anti-apoptotic proteins such as MYC and MCL1. PRT2527 is a potent, selective CDK9 inhibitor currently in early clinical development. We evaluated its preclinical activity in marginal zone lymphoma (MZL) models, including cell lines with acquired resistance to BTK, PI3K, and BCL2 inhibitors. S...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5a617a96-fef7-5772-9ec5-479a9fd185cc
DOI: 10.64898/2026.02.10.705084

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CDK9 pharmacological inhibition with PRT2527 has antitumor activity in marginal zone lymphoma models and can improve the effects of BTK, PI3K, and BCL2 inhibitorsDOI 10.64898/2026.02.10.705084Read

Dual targeting of BTK and BCL2 enhances apoptosis in marginal zone lymphoma models: preclinical activity of BGB-16673 and sonrotoclaxSemantic proximity Read

High-Throughput Screening Identifies PLK1 Inhibition as a Strategy to Potentiate BTK Blockade in Marginal Zone LymphomaSemantic proximity Read

The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphomaSemantic proximity Read

Cyclin-Dependent Kinase 5 Contributes to Bruton’s Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell LymphomaSemantic proximity Read

Optimizing therapy for nodal marginal zone lymphomaSemantic proximity Read

CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer AgentsSemantic proximity Read

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developmentsSemantic proximity Read

CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignanciesSemantic proximity Read

Addressing Transcriptional Dysregulation in Cancer through CDK9 InhibitionSemantic proximity Read

CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphomaSemantic proximity Read

VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemiaSemantic proximity Read

The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphomaSemantic proximity Read